Aug 6 (Reuters) - Bio-Techne TECH.O reported better-than-expected fourth-quarter revenue and profit on Wednesday, helped by steady demand for its proteins, antibodies and other products for research.
The Minneapolis, Minnesota-based company develops and makes products used in medical research, drug development and diagnostics.
Larger peers Thermo Fisher TMO.N and Danaher DHR.N last month flagged robust demand across regions for their drug development products such as instruments and analytical tools after two years of weak biotech funding.
Despite ongoing market uncertainty, Bio-Techne reported strong performance in its cell therapy and protein analysis instrumentation units, supported by a resilient pharma market, CEO Kim Kelderman said in a statement.
On an adjusted basis, the company posted a profit of 53 cents per share, beating analysts' average estimate of 50 cents, according to data compiled by LSEG data.
Revenue was up 3.6% at $316.96 million, ahead of estimates of $315.60 million, driven by its protein sciences unit. The company's largest segment develops and manufactures biological compounds used for research and diagnostics.
Late on Tuesday, Bio-Techne said Belgium-based diagnostics firm Mdxhealth SA MDXH.O will buy its Exosome Diagnostics business in an all-stock deal valued at $5 million.
The deal will allow the company to increase its focus on high-growth areas, particularly tools for research and precision diagnostics, Kelderman said.
The transaction is expected to close in the next quarter.
(Reporting by Siddhi Mahatole in Bengaluru)
((siddhi.mahatole@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。